We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

INFQ:NYSEInfleqtion, Inc. Analysis

Data as of 2026-08-16 - not real-time

$12.86

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Infleqtion, Inc. is priced at $12.86 and its moving averages line up in bearish order, the shorter trailing the longer. The last 30 days have gained 4.5%. With RSI at 60.7 the momentum picture is approaching overbought, alongside a bullish MACD signal. Price has been bracketed by support at $8.78 and resistance at $13.20.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 60.2% above today's level. Revenue is growing at 116.4% on a -179.9% profit margin.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 94.4%, a beta of 4.30 and a maximum drawdown of 55.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
The horizons line up on hold — conviction 2 out of 10.

Top Market Events

The Caledonian Record4dInfleqtion Reports Record Q2 Revenue, Raises 2026 Outlook as Quantum Commercialization...Infleqtion Inc. NYSE:INFQ is one of the 10 Stocks Investors Are Running Away From. Infleqtion kicked off the trading...7dInfleqtion: My New Favorite Quantum StockInfleqtion stock outlook: scalable neutral-atom quantum tech, U.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading above the 200-day average of 12.41
  • MACD momentum is positive

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading above the 200-day average of 12.41
  • Analyst targets imply +60.2% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • Negative profit margin of -179.9%
  • Analyst targets imply +60.2% versus the current price
  • Revenue growth of +116.4%

Key Metrics & Analysis

Financial Health

Revenue Growth116.40%
Profit Margin-179.87%
P/E Ratio-58.8
Debt/Equity2.52
P/B Ratio4.8
Op. Cash Flow$-20392000
Industry P/E36.5

Technical Analysis

TrendBearish
RSI60.7
Support$8.78
Resistance$13.20
MA 20$10.65
MA 50$11.99
MA 200$12.41
MACDBullish
VolumeStable
Fear & Greed Index95.98

Valuation

Target Price$20.60
Upside/Downside60.19%
GradeFair
TypeGrowth

Risk Assessment

Beta4.30
Volatility94.43%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.